Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Canaccord Genuity Downgrades T2 Biosystems, Inc (TTOO) to Hold
-
T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference
-
T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
-
T2 Biosystems to Participate in the Canaccord Genuity 41st Annual Growth Conference
-
T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum
-
T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference
-
T2 Biosystems to Present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
-
T2 Biosystems, Inc (TTOO) PT Raised to $3.50 at Canaccord Genuity
-
T2 Biosystems, Inc (TTOO) PT Lowered to $2.50 at Canaccord Genuity
-
T2 Biosystems Reports Second Quarter 2019 Financial Results and Provides Corporate Update
-
T2 Biosystems to Present at the Canaccord Genuity Growth Conference
-
T2 Biosystems, Inc (TTOO) PT Lowered to $5 at Canaccord Genuity
-
T2 Biosystems, Inc (TTOO ) PT Lowered to $6 at Canaccord Genuity
-
T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
-
T2 Biosystems to Participate in Two Upcoming Conferences
-
T2 Biosystems Announces Closing of Public Offering of Common Stock
-
T2 Biosystems (TTOO) Prices 6.1M Shares at $7.50
-
T2 Biosystems Announces Pricing of Public Offering of Common Stock
-
T2 Biosystems (TTOO) Announces Proposed 5.65M Share Common Offering
-
T2 Biosystems Announces Proposed Public Offering of Common Stock
-
T2 Biosystems, Inc (TTOO) PT Raised to $10 at Canaccord Genuity
-
T2 Biosystems, Inc (TTOO) PT Raised to $8 at Canaccord Genuity
-
T2 Biosystems, Inc (TTOO) PT Raised to $7 at Canaccord Genuity Citing Model Roll Forward to 2020 Estimates
-
T2 Biosystems (TTOO) Prices 4.38M Common Stock Offering at $4/Share
-
T2 Biosystems Announces Pricing of Public Offering of Common Stock
-
T2 Biosystems (TTOO) Plans Offering of Common Stock
-
T2 Biosystems Announces Proposed Public Offering of Common Stock
-
T2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference
-
T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
-
T2 Biosystems to Present at the Canaccord Genuity Growth Conference
-
Notable Analyst Rating Changes 2/10: (TDG) (DF) (SCTY) Upgraded; (XL) (KNX) (AINV) Downgraded
-
Canaccord Genuity Starts T2 Biosystems, Inc (TTOO) at Buy, PT $15
-
T2 Biosystems (TTOO) Announces Closing of 3.5M Common Stock Offering
-
T2 Biosystems Announces Closing of Public Offering of Common Stock
-
T2 Biosystems Announces Closing of Public Offering of Common Stock
-
T2 Biosystems (TTOO) Prices 3.5M Common Stock Offering at $9.75/Share
-
T2 Biosystems Announces Pricing of Public Offering of Common Stock
-
T2 Biosystems (TTOO) Commences 3.5M Share Common Stock Offering
-
T2 Biosystems Announces Proposed Public Offering of Common Stock
-
T2 Biosystems to Present at Upcoming Investor Conferences
-
Canaccord Genuity Starts T2 Biosystems, Inc (TTOO) at Buy
-
T2 Biosystems to Present at Canaccord Genuity Growth Conference
-
T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

